泛癌分析LDHB基因在预测患者预后和免疫治疗反应中的应用

摘要/Abstract

摘要： 目的通过泛癌分析确定LDHB基因是预测肿瘤患者预后和免疫治疗反应的有价值的生物标志物。方法在癌症基因组图谱的镜像数据库中,下载33种肿瘤的转录组测序数据及对应患者的临床信息及肿瘤突变的数据,使用R软件进行统计分析,研究LDHB在33种肿瘤细胞中的表达量及其与正常细胞之间表达活性的差异,分析LDHB在泛癌中的预后价值,评估LDHB表达量与肿瘤突变负荷和微卫星不稳定性间的关系。结果在多种肿瘤组织中LDHB基因表达水平升高,且与不良预后密切相关。在特定的肿瘤组织中LDHB基因与肿瘤突变负荷和微卫星不稳定性具有明显相关性,在胸腺癌（THYM）中r=-0.7,P<0.001,在DLBC中r=0.4,P<0.01。结论 LDHB可作为预测患者预后和免疫治疗反应的有价值的生物标志物。LDHB基因的测定有助于早期识别出肿瘤高危患者,及时制订个性化的预防和治疗方案,加强随访将有望改善疾病预后。同时,LDHB对于肿瘤免疫治疗的药物反应具有相关作用,可用于指导和监测免疫检查点抑制剂的选择和作用效果。

关键词: LDHB基因, 泛癌分析, 预后评估, 治疗反应

中图分类号:

陈念, 蔡凯, 廖小雯, 覃碧芳, 郑恒. 泛癌分析LDHB基因在预测患者预后和免疫治疗反应中的应用[J]. 中华养生保健, 2023, 41(13): 35-39.

参考文献

[1] GANAPATHY-KANNIAPPAN S, GESCHWIND J.Tumor glycolysis as a target for cancer therapy: Progress and prospects[J]. Molecular Cancer, 2013,12(1):152.
[2] PELICANO H, MARTIN D S, XU R H, et al.Glycolysis inhibition for anticancer treatment[J]. Oncogene,2006,25(34):4633-4646.
[3] DRENT M, COBBEN N, HENDERSON R F, et al.Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation[J]. European Respiratory Journal,1996,9(8):1736-1742.
[4] FORKASIEWICZ A, DOROCIAK M, STACH K, et al.The usefulness of lactate dehydrogenase measurements in current oncological practice[J]. Zeitschrift fur Arznei- und Gewurzpflanzen,2020,25(1):35.
[5] KAWAMOTO M.Breast cancer diagnosis by lactate dehydrogenase isozymes in nipple discharge[J]. Cancer,1994,73(7):1836-1841.
[6] ŽDRALEVIĆ M, BRAND A, DI IANNI L, et al.Double genetic disruption of lactate dehydrogenase A and B is required to ablate the ‘Warburg effect’ restricting tumor growth to oxidative metabolism[J]. Journal of Biological Chemistry,2018,293(41):15947-15961.
[7] URBAŃSKA K, ORZECHOWSKI A. Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells[J]. International journal of molecular sciences,2019,20(9):2085.
[8] MCCLELAND M L, ADLER A S, DEMING L, et al.Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas[J]. Clinical Cancer Research,2013,19(4):773-784.
[9] SHENG H, TANG W.Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents[J]. Recent patents on anti-cancer drug discovery, 2016,11(3):297-308.
[10] 骆平,查小军,汪宏. mTOR和LDHB在肝细胞癌组织中的表达及意义[J]. 安徽医学,2012,33(8):965-969.
[11] 聂佳琪,潘凤,李晓宁,等. LDHA及LDHB对胃癌组织中免疫微环境的影响及临床意义[J]. 临床与实验病理学杂志,2022,38(4):421-426.
[12] KALEZIC A, UDICKI M, SRDIC GALIC B, et al.Lactate Metabolism in Breast Cancer Microenvironment: Contribution Focused on Associated Adipose Tissue and Obesity[J]. International Journal of Molecular Sciences,2020,21(24):9676.
[13] LIU J, CHEN G, LIU Z, et al.Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer[J]. Cancer Res,2018,78(16):4459-4470.
[14] GUYON J, FERNANDEZ-MONCADA I, LARRIEU C M, et al.Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis[J]. EMBO Mol Med,2022,14(12):e15343.
[15] GIVECHIAN K B, CHAD G, STEVE B, et al. Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression[J]. Neuro-Oncology Advances,2020,3(1):vdaa162 .
[16] RUTZKY L P, SICILIANO M J.Various isozyme gene expression patterns among human colorectal adenocarcinoma cell lines and tissues[J]. J Natl Cancer Inst,1982,68(1):81-90.
[17] LIAO A C, LI C F, SHEN K H, et al.Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma[J]. Pathology,2011,43(7):707-712.
[18] LI PETRI G, EL HASSOUNI B, SCIARRILLO R, et al.Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds[J]. Br J Cancer,2020,123(4):644-656.
[19] CALLAHAN M, POSTOW M, WOLCHOK J.Targeting T Cell Co-receptors for Cancer Therapy[J]. Immunity,2016,44(5):1069-1078.
[20] JIAO X D, ZHANG X C, QIN B D, et al.Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types[J]. Annals of translational medicine,2020,8(14):860.
[21] LAGOS G G, IZAR B, RIZVI N A.Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy[J]. American Society of Clinical Oncology Educational Book,2020,40:1-11.
[22] OVERMAN M J, MCDERMOTT R, LEACH J L, et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncology,2017,18(9):1182-1191.
[23] SAMSTEIN R M, LEE C H, SHOUSHTARI A N, et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Genet,2019,51(2):202-206.
[24] MCGRAIL D J, PILIÉ P G, RASHID N U, et al.High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types[J]. Annals of Oncology,2021,32(5):661-672.
[25] XU Q, CHEN S, HU Y, et al.Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer[J]. Front Immunol,2021,12:711433.
[26] COLOMBO A R, HAV M, SINGH M, et al.Single-cell spatial analysis of tumor immune architecture in diffuse large B cell lymphoma[J]. Blood Adv,2022,6(16):4675-4690.
[27] ZHANG X, SHI M, CHEN T, et al.Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy[J]. Molecular Therapy - Nucleic Acids,2020,22:298-309.
[28] SENA L A, FOUNTAIN J, ISAACSSON VELHO P, et al.Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer[J]. Oncologist,2021,26(2):e270-e278.
[29] ROUSSET-ROUVIERE S, ROCHIGNEUX P, CHRÉTIEN A S, et al. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology[J]. Biomedicines,2021,9(6):632.